A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells
Eun A Choi(Ulsan College), Suhwan Chang(Ulsan College), Shree Ram Singh(Indian Institute of Technology BHU), Song Cheol Kim(Ulsan College), Eun Ji Lee(Ulsan College), Yeon-Sook Choi(Ulsan College)
Cited by 18
Related Papers
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577
A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts
|Gastroenterology|2015|472
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis
|JNCI Journal of the National Cancer Institute|2019|299
A 3D-printed local drug delivery patch for pancreatic cancer growth suppression
|Journal of Controlled Release|2016|260